XRCC1 overexpression has been shown to increase resistance to DNA-damaging chemotherapeutics in gastric and ovarian cancers, while low XRCC1 is correlated with hypersensitivity to DNA-damaging agents [7,8,9,10,11,12]. Here, XRCC1 is linked to ovarian cancer.